Which botanicals or other unconventional anticancer agents should we take to clinical trial? Article Report uri icon


MeSH Major

  • Clinical Competence
  • Prostatectomy
  • Prostatic Neoplasms


  • There is significant public and scientific interest as regards unconventional anticancer agents (complementary and alternative medicine [CAM] agents). This article describes five principles pertaining to the question of which CAM agents should be taken to clinical trial: (1) many CAM agents have been proposed as cancer treatments, far more than could possibly be studied in clinical trials; (2) claims by patients or practitioners are generally unhelpful in choosing which CAM agents to test; (3) laboratory studies can help determine which CAM agents to take to trial and with which cointerventions; (4) preliminary laboratory studies are essential to confirm safety before trials can be considered; and (5) the vast majority of anticancer CAM agents will be ineffective; our aim should be to discard agents from consideration as rapidly as possible.

publication date

  • June 2007



  • Report


Digital Object Identifier (DOI)

  • 10.2310/7200.2007.011

PubMed ID

  • 17761132

Additional Document Info

start page

  • 125

end page

  • 9


  • 5


  • 3